These drugs are glucagon-like peptide-1 receptor-1 agonists (GLP-1RAs) designed to lower body weight in patients with type 2 diabetes mellitus (T2DM), and Liraglutide is the first GLP-1RA approved for the treatment of obesity in people with and without type 2 diabetes mellitus (T2DM) [40]. This evidence concerns the gene GLP1R and Obesity.